Information concerning the prescnptions for theophylline preparations for a group of 80 inpatients and 55 outpatients were examined. Slow-release preparations were overwhelmingly preferred. The majority of patients were receiving low daily doses of theophylline or equivalent, and serum drug level monitoring was almost non-existent.
Introduction
There is a wide variety of theophylline preparations available for the treatment of reversible obstructive airways disease, including both conventional and slow-release preparations. This study was designed to assess the type of preparation used, the dosage regimen employed and the extent of rational prescribing.
Methods
Prescribing habits were investigated for inpatients and outpatients separately. In both cases prescriptions were not included more than once for anyone patient.
Inpatients: During a three-month period all prescriptions for oral theophylline preparations were recorded prospectively by the ward pharmacists of a district general hospital. The case notes were then reviewed and information obtained concerning the preparation, dose and degree of control of airways obstruction, where available. The presence or absence of a serum theophylline assay result was also noted.
Outpatients: A retrospective prescription search was performed in a teaching hospital, covering four separate months over a two-year period for which records remained available. The preparation and dose were noted for each prescription.
Results

Inpatients:
The mean age of the 80 patients included in the study was 72 years. There were 52 men, mean age 75.9 years (range 17-84 years), and 28 females, mean age 64.8 years (range 39-85 years). The vast majority (77/80) were receiving multiple-dose regimens, most receiving slow-release preparations twice daily (71/80). Only a minority of these (10/71) were receiving more than 400 mg theophylline daily (Table I ). In 16/80 patients there was definite evidence from the case notes of inadequate control of airways obstruction. Amongst these patients, almost all (15/16) were receiving less than 400 mg theophylline daily (Table I ). In the whole group only one patient, who was inadequately controlled, had a serum theophylline level measured.
Outpatients: During the four months under study, prescriptions for 55 outpatients were identified, the majority being for slow-release preparations (52/55). More than half of the prescriptions for twice-daily administration (28/48) were for daily doses of theophylline of less than 400 mg (Table 2) . 
Discussion
It is clear that slow-release theophylline preparations are now widely used compared with conventional preparations. As well as increasing compliance and reducing the 'burden of excessive tablet-taking for the patient, the slow-release preparations are likely to have improved the effectiveness of this form of therapy by maintaining adequate serum concentrations of theophylline for longer periods. Although slow-release preparations should be taken twelve-hourly, in the inpatient study where dosing times could be accurately studied, 14/71 patients taking such preparations had one dosing interval each day that was longer than twelve hours.
The starting dose of slow-release theophylline preparations, recommended by the British National Formulary, is one tablet twice daily. Depending on the preparation concerned, this is equivalent to 350-500 mg of theophylline daily. We have arbitrarily taken a daily dose of 400 mg theophylline as the dose above which inadequately controlled patients should be treated. The serum concentration needed to achieve maximum bronchodilator effect, in a group of 7 asthmatic patients, was between 8 and 20,ug/ml (Jenne et al. 1972) . The dose of theophylline needed to maintain the serum concentration above 8 ,ug/ml is usually at least 600 mg daily (Jackson & Wright 1983) . However, excluding those taking a night-time dose only. 61/77 (79%) inpatients and 28/48 (58%) outpatients were receiving less than 400 mg daily. Further, 16/80 (20%) of the inpatients were definitely known to have symptoms of their airways obstruction, yet only one of these received a dose higher than the recommended starting dose. Only one patient in the inpatient study had a serum theophylline concentration measured, despite the readily available assay service. The likely explanation for this is lack of awareness of the service, rather than a decision not to make use of it.
From these observations it is likely that consistent underdosing is a major problem with theophylline. Whilst the prevalence of adverse effects rises with increasing dosage, higher doses would achieve better control of symptoms, assuming a reversible component to the 
